{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(2)"],"submitter":["Zheng Q"],"pubmed_abstract":["Constitutive activation of signal transducer and activator of transcription 3 (STAT3) is a common feature in human non-small cell lung cancer (NSCLC). STAT3 plays an important role in cancer progression as a driver oncogene and acquired resistance of targeted therapies as an alternatively activated pathway. W2014-S with pharmacophore structure of imidazopyridine, which was firstly reported to be utilized in STAT3 inhibitor discovery, was screened out as a potent STAT3 inhibitor from a library of small molecules. The aim of this study is to investigate the antitumor activities and mechanisms of W2014-S in NSCLC and effect on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) resistance <i>in vitro</i> and <i>in vivo</i>. <b>Methods:</b> SPR analysis, Co-immunoprecipitat"],"journal":["Theranostics"],"pagination":["824-840"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7738869"],"repository":["biostudies-literature"],"pubmed_title":["A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance."],"pmcid":["PMC7738869"],"pubmed_authors":["Ouyang S","Huang J","Shi S","Hu W","Mo J","Liu P","Zheng Q","Dong H","Zhang Y","Zhu K","Zhang X","Qu X","Wang Y"],"additional_accession":[]},"is_claimable":false,"name":"A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.","description":"Constitutive activation of signal transducer and activator of transcription 3 (STAT3) is a common feature in human non-small cell lung cancer (NSCLC). STAT3 plays an important role in cancer progression as a driver oncogene and acquired resistance of targeted therapies as an alternatively activated pathway. W2014-S with pharmacophore structure of imidazopyridine, which was firstly reported to be utilized in STAT3 inhibitor discovery, was screened out as a potent STAT3 inhibitor from a library of small molecules. The aim of this study is to investigate the antitumor activities and mechanisms of W2014-S in NSCLC and effect on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) resistance <i>in vitro</i> and <i>in vivo</i>. <b>Methods:</b> SPR analysis, Co-immunoprecipitat","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-05-02T23:30:16.481Z","creation":"2021-02-20T19:43:07Z"},"accession":"S-EPMC7738869","cross_references":{"pubmed":["33391507"],"doi":["10.7150/thno.49600"]}}